KIMI IGUCHI - 15 Jun 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
Issuer symbol
SAGE
Transactions as of
15 Jun 2021
Net transactions value
-$41,534
Form type
4
Filing time
17 Jun 2021, 09:12:02 UTC
Next filing
21 Oct 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Options Exercise $4,080 +3,000 +8.1% $1.36 39,855 15 Jun 2021 Direct
transaction SAGE Common Stock Award $0 +3,500 +8.8% $0.000000 43,355 15 Jun 2021 Direct F1
transaction SAGE Common Stock Tax liability $48,334 -822 -1.9% $58.80 42,533 15 Jun 2021 Direct
transaction SAGE Common Stock Options Exercise $2,720 +2,000 +4.7% $1.36 44,533 16 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Options Exercise $0 -3,000 -16% $0.000000 16,047 15 Jun 2021 Common Stock 3,000 $1.36 Direct F2
transaction SAGE Stock Option (Right to Buy) Options Exercise $0 -2,000 -12% $0.000000 14,047 16 Jun 2021 Common Stock 2,000 $1.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 8,750 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 3,500 shares.
F2 The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on July 23, 2016.